News

Panel supports lower doses of novel insomnia drug


 

FROM AN FDA ADVISORY PANEL MEETING

Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but not at this meeting.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Zolpidem Linked to Higher Inpatient Fall Rates
MDedge Family Medicine
Acetazolamide and CPAP combined improve OSA at high altitude
MDedge Family Medicine
FDA requires lower recommended doses for certain sleep drugs
MDedge Family Medicine
Renal denervation improves glucose metabolism, sleep apnea
MDedge Family Medicine
CPAP vs. appliances for sleep apnea
MDedge Family Medicine
For hypertension, pair CPAP with weight loss
MDedge Family Medicine
REM sleep problems predict Parkinson's, Lewy body dementia
MDedge Family Medicine
Older patients report frequent insomnia, sleep treatment use
MDedge Family Medicine
Preclinical brain amyloid deposition linked to poor sleep
MDedge Family Medicine
Early adenotonsillectomy beneficial for obstructive sleep apnea syndrome
MDedge Family Medicine